EICHORCondition: Relapsed/Refractory Large B-cell Lymphoma · Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd.
This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy.
This description comes directly from the study's public registry record.
Zhizhong Geng · 8616601956551 · eric.geng@fosunkairos.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The Frist Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| Shanghai Jiaotong University School of Medicine Ruijin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospotal Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07606937